Company news

BioXcel Therapeutics, Inc. news in 2025

BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

December 3, 2025

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

November 12, 2025

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

October 14, 2025

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

October 13, 2025

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

September 18, 2025

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

September 10, 2025

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

August 27, 2025

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

August 26, 2025

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

August 19, 2025

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

August 18, 2025

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

August 13, 2025

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

August 12, 2025

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

August 11, 2025

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

August 6, 2025

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

August 1, 2025

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

July 21, 2025

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

July 1, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 27, 2025

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

March 27, 2025

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

March 11, 2025

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

March 7, 2025

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

March 4, 2025

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

March 3, 2025

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

March 3, 2025

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

February 28, 2025

BioXcel Therapeutics Announces Reverse Stock Split

February 5, 2025

BioXcel Therapeutics Provides Clinical and Business Update

February 4, 2025

Decks in 2025